0 22 Phosphatidylinositides Phosphatidylinositide NNP 23 27 bind bind VBP 28 30 to to TO 31 37 plasma plasma NN 38 46 membrane membrane NN 47 51 CD14 cd14 NN 52 55 and and CC 56 59 can can MD 60 67 prevent prevent VB 68 76 monocyte monocyte NN 77 87 activation activation NN 88 90 by by IN 91 100 bacterial bacterial JJ 101 119 lipopolysaccharide lipopolysaccharide NN 119 120 . . . 122 130 Although although IN 131 140 bacterial bacterial JJ 141 160 lipopolysaccharides lipopolysaccharide NNS 161 162 ( ( ( 162 165 LPS LPS NNP 165 166 ) ) ) 167 170 and and CC 171 178 several several JJ 179 184 other other JJ 185 194 microbial microbial JJ 195 203 agonists agonist NNS 204 207 can can MD 208 212 bind bind VB 213 215 to to TO 216 221 mCD14 mcd14 NN 222 223 ( ( ( 223 231 membrane membrane NN 232 236 CD14 cd14 NN 236 237 ) ) ) 237 238 , , , 239 240 a a DT 241 253 cell-surface cell-surface JJ 254 262 receptor receptor NN 263 268 found find VBN 269 280 principally principally RB 281 283 on on IN 284 293 monocytes monocyte NNS 294 297 and and CC 298 309 neutrophils neutrophil NNS 309 310 , , , 311 323 host-derived host-derived JJ 324 329 mCD14 mcd14 NN 330 337 ligands ligand NNS 338 341 are be VBP 342 348 poorly poorly RB 349 356 defined define VBN 356 357 . . . 358 360 We we PRP 361 367 report report VBP 368 372 here here RB 373 377 that that IN 378 398 phosphatidylinositol phosphatidylinositol NN 399 400 ( ( ( 400 406 PtdIns PtdIns NNP 406 407 ) ) ) 407 408 , , , 409 441 phosphatidylinositol-4-phosphate phosphatidylinositol-4-phosphate NN 441 442 , , , 443 446 and and CC 447 452 other other JJ 453 475 phosphatidylinositides phosphatidylinositide NNS 476 479 can can MD 480 484 bind bind VB 485 487 to to TO 488 493 mCD14 mcd14 NN 493 494 . . . 495 513 Phosphatidylserine Phosphatidylserine NNP 514 515 ( ( ( 515 517 PS PS NNP 517 518 ) ) ) 518 519 , , , 520 527 another another DT 528 535 anionic anionic JJ 536 555 glycerophospholipid glycerophospholipid NN 555 556 , , , 557 562 binds bind VBZ 563 565 to to TO 566 571 mCD14 mcd14 NN 572 576 with with IN 577 582 lower low JJR 583 591 apparent apparent JJ 592 600 affinity affinity NN 601 605 than than IN 606 610 does do VBZ 611 617 PtdIns PtdIns NNP 617 618 . . . 619 630 LPS-binding lps-binding JJ 631 638 protein protein NN 638 639 , , , 640 641 a a DT 642 647 lipid lipid NN 648 656 transfer transfer NN 657 664 protein protein NN 665 670 found find VBN 671 673 in in IN 674 679 serum serum NN 679 680 , , , 681 692 facilitates facilitate VBZ 693 697 both both CC 698 701 PS- ps- NN 702 705 and and CC 706 718 PtdIns-mCD14 ptdins-mcd14 NN 719 726 binding binding NN 726 727 . . . 728 734 PtdIns ptdins NN 735 742 binding binding NN 743 745 to to TO 746 751 mCD14 mcd14 NN 752 755 can can MD 756 758 be be VB 759 766 blocked block VBN 767 769 by by IN 770 779 anti-CD14 anti-cd14 JJ 780 790 monoclonal monoclonal JJ 791 801 antibodies antibody NNS 802 806 that that WDT 807 814 inhibit inhibit VBP 815 824 LPS-mCD14 lps-mcd14 NN 825 832 binding binding NN 832 833 , , , 834 837 and and CC 838 844 PtdIns PtdIns NNP 845 848 can can MD 849 856 inhibit inhibit VB 857 861 both both CC 862 871 LPS-mCD14 lps-mcd14 NN 872 879 binding binding NN 880 883 and and CC 884 895 LPS-induced lps-induced JJ 896 905 responses response NNS 906 908 in in IN 909 918 monocytes monocyte NNS 918 919 . . . 920 938 Serum-equilibrated serum-equilibrated JJ 939 945 PtdIns PtdIns NNP 946 950 also also RB 951 956 binds bind VBZ 957 959 to to TO 960 976 mCD14-expressing mcd14-expressing JJ 977 982 cells cell NNS 982 983 , , , 984 991 raising raise VBG 992 995 the the DT 996 1007 possibility possibility NN 1008 1012 that that IN 1013 1023 endogenous endogenous JJ 1024 1030 PtdIns ptdins NN 1031 1034 may may MD 1035 1043 modulate modulate VB 1044 1052 cellular cellular JJ 1053 1062 responses response NNS 1063 1065 to to TO 1066 1069 LPS lps NN 1070 1073 and and CC 1074 1079 other other JJ 1080 1085 mCD14 mcd14 NN 1086 1093 ligands ligand NNS 1094 1096 in in FW 1097 1101 vivo vivo FW 1101 1102 . . .